Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Depreciation & Amortization (CF): 2016-2025

Historic Depreciation & Amortization (CF) for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to $42,000.

  • Summit Therapeutics' Depreciation & Amortization (CF) rose 110.00% to $42,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $126,000, marking a year-over-year increase of 29.90%. This contributed to the annual value of $89,000 for FY2024, which is 55.05% down from last year.
  • As of Q3 2025, Summit Therapeutics' Depreciation & Amortization (CF) stood at $42,000, which was up 13.51% from $37,000 recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Depreciation & Amortization (CF) peaked at $99,000 during Q2 2022, and registered a low of $20,000 during Q2 2024.
  • For the 3-year period, Summit Therapeutics' Depreciation & Amortization (CF) averaged around $35,545, with its median value being $30,000 (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first spiked by 125.71% in 2021, then slumped by 70.00% in 2024.
  • Quarterly analysis of 5 years shows Summit Therapeutics' Depreciation & Amortization (CF) stood at $79,000 in 2021, then grew by 11.39% to $88,000 in 2022, then tumbled by 65.91% to $30,000 in 2023, then decreased by 26.67% to $22,000 in 2024, then skyrocketed by 110.00% to $42,000 in 2025.
  • Its Depreciation & Amortization (CF) was $42,000 in Q3 2025, compared to $37,000 in Q2 2025 and $25,000 in Q1 2025.